source
- Tango Therapeutics reports strong early response with vopimetostat plus daraxonrasib in pancreatic cancer trialTango Therapeutics announced that its experimental epigenetic drug vopimetostat, when combined with Revolution Medicines' KRAS inhibitor daraxonrasib, produced high response rates in a small pancre…
- Biopharma must pair innovation with operational readiness to scale therapiesThe article argues that breakthrough science alone no longer guarantees success in biopharma. Companies now face pressure to turn discoveries into reliably manufactured, delivered, and scalable pro…